Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure
Pneumococcal conjugate vaccines (PCVs) have transformed the prevention of Streptococcus pneumoniae infections, yet challenges such as serotype replacement and vaccine escape demand their continual evaluation for improvement. This review outlines the core approaches used to assess pneumococcal vaccin...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2545032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849770289261445120 |
|---|---|
| author | Feroze A. Ganaie Moon H. Nahm |
| author_facet | Feroze A. Ganaie Moon H. Nahm |
| author_sort | Feroze A. Ganaie |
| collection | DOAJ |
| description | Pneumococcal conjugate vaccines (PCVs) have transformed the prevention of Streptococcus pneumoniae infections, yet challenges such as serotype replacement and vaccine escape demand their continual evaluation for improvement. This review outlines the core approaches used to assess pneumococcal vaccine efficacy, from early-stage development to licensure. The WHO-ELISA is the established method for quantifying serotype-specific IgG levels, while the opsonophagocytic assay assess functional antibody activity and serve as an independent correlate of protection across both vaccine and cross-reactive serotypes. Assessment of antibody avidity and memory B-cell responses offer additional insights into immune quality and durability. Together, these methodologies form a robust framework for evaluating current and next-generation PCVs, supporting evidence-based vaccine licensure, informing public health strategies, and addressing evolving challenges in pneumococcal disease prevention. |
| format | Article |
| id | doaj-art-7d1ec059af9c4c6f8be36a411a0ffa34 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-7d1ec059af9c4c6f8be36a411a0ffa342025-08-20T03:03:04ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2545032Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensureFeroze A. Ganaie0Moon H. Nahm1Division of Pulmonary/Allergy/Critical Care, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USADivision of Pulmonary/Allergy/Critical Care, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USAPneumococcal conjugate vaccines (PCVs) have transformed the prevention of Streptococcus pneumoniae infections, yet challenges such as serotype replacement and vaccine escape demand their continual evaluation for improvement. This review outlines the core approaches used to assess pneumococcal vaccine efficacy, from early-stage development to licensure. The WHO-ELISA is the established method for quantifying serotype-specific IgG levels, while the opsonophagocytic assay assess functional antibody activity and serve as an independent correlate of protection across both vaccine and cross-reactive serotypes. Assessment of antibody avidity and memory B-cell responses offer additional insights into immune quality and durability. Together, these methodologies form a robust framework for evaluating current and next-generation PCVs, supporting evidence-based vaccine licensure, informing public health strategies, and addressing evolving challenges in pneumococcal disease prevention.https://www.tandfonline.com/doi/10.1080/21645515.2025.2545032Streptococcus pneumoniaeWHO-ELISAopsonophagocytic assaypneumococcal conjugate vaccinesimmune response |
| spellingShingle | Feroze A. Ganaie Moon H. Nahm Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure Human Vaccines & Immunotherapeutics Streptococcus pneumoniae WHO-ELISA opsonophagocytic assay pneumococcal conjugate vaccines immune response |
| title | Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure |
| title_full | Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure |
| title_fullStr | Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure |
| title_full_unstemmed | Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure |
| title_short | Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure |
| title_sort | approaches to assess new pneumococcal vaccines for immunogenicity development and licensure |
| topic | Streptococcus pneumoniae WHO-ELISA opsonophagocytic assay pneumococcal conjugate vaccines immune response |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2545032 |
| work_keys_str_mv | AT ferozeaganaie approachestoassessnewpneumococcalvaccinesforimmunogenicitydevelopmentandlicensure AT moonhnahm approachestoassessnewpneumococcalvaccinesforimmunogenicitydevelopmentandlicensure |